血液灌流联合血液滤过治疗高脂血症胰腺炎的研究进展
作者:
通讯作者:
作者单位:

1.华中科技大学同济医学院附属协和医院 胰腺外科,湖北 武汉 430022;2.武汉大学基础医学院 生理学系,湖北 武汉 430072

作者简介:

许威,华中科技大学同济医学院附属协和医院护师,主要从事重症急性胰腺炎方面的研究。

基金项目:


Research progress of hemoperfusion combined with hemofiltration in treatment of hyperlipidemic pancreatitis
Author:
Affiliation:

1.Department of Pancreatic Surgery, Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China;2.Department of Physiology, School of Basic Medical Sciences, Wuhan University, Wuhan 430072, China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 音频文件
  • |
  • 视频文件
    摘要:

    高脂血症胰腺炎(HLP)的临床过程不同于其他病因引起的胰腺炎,多器官功能不全综合征(MODS)发生率以及出院后复发率均较非HLP高,且主要脏器并发症与血清甘油三酯(TG)水平呈正相关。其治疗关键在于迅速降低TG水平和阻断全身炎症反应。而血液灌流联合血液滤过治疗可以有效清除血TG和炎症因子,已成为治疗HLP的重要手段。笔者就血液灌流联合血液滤过在HLP治疗中的应用进展进行综述,以期为临床提供参考。

    Abstract:

    The clinical process of hyperlipidemic pancreatitis (HLP) is different from those triggered by other causes. Its incidence rates of multiple organ dysfunction syndrome (MODS) and recurrence after hospital discharge were higher than those of non-HLP, and the complications affecting the major organs are positively correlated with the level of serum triglyceride (TG). The key to its treatment is to rapidly reduce the TG level and block systemic inflammatory response. Hemoperfusion combined with hemofiltration can effectively remove blood TG and inflammatory factors, and has become an important approach for the treatment of HLP. Herein, the authors address the application progress of combination of hemoperfusion and hemofiltration in the treatment of HLP, so as to provide referential information for clinical use.

    参考文献
    相似文献
    引证文献
引用本文

许威,曾梦柳.血液灌流联合血液滤过治疗高脂血症胰腺炎的研究进展[J].中国普通外科杂志,2022,31(3):397-404.
DOI:10.7659/j. issn.1005-6947.2022.03.013

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2021-04-23
  • 最后修改日期:2021-09-20
  • 录用日期:
  • 在线发布日期: 2022-04-02